Home » FDA Lays Out New Guidance on Cancer Endpoints
FDA Lays Out New Guidance on Cancer Endpoints
Cancer trials that rely on event-free survival and complete response to treatment as surrogate endpoints will be acceptable to FDA reviewers, the agency said in a new final guidance.
The FDA also is willing to consider emerging endpoints such as symptom improvement or relief, minimal residual disease or metastasis-free survival, the 19-page document states.
The guidance replaces a 2007 document to provide updated thinking on an industry that has evolved rapidly in the past decade or more, the agency said.
Upcoming Events
-
07May
-
14May
-
30May